Over the past few years, extensive evidence, including the clinical findings that MEF2 levels were robustly decreased in postmortem brain of Parkinson’s patients (She et al., 2011), has suggested that inhibition of MEF2, and MEF2D in particular, is neuropathologically linked to PD (Yang et al., 2009), Moreover, MEF2D plays a critical role in neuronal survival in various cellular and animal experimental models related to PD (Mount et al., 2013; Hu et al., 2015b; Guo et al., 2017). Here, MEF2A is linked to Parkinsonism.